Invention Grant
- Patent Title: Nitrogenous-ring acylguanidine derivative
- Patent Title (中): 氮环酰基胍衍生物
-
Application No.: US13388872Application Date: 2010-08-05
-
Publication No.: US08853242B2Publication Date: 2014-10-07
- Inventor: Isao Kinoyama , Takehiro Miyazaki , Yohei Koganemaru , Takuya Washio , Wataru Hamaguchi
- Applicant: Isao Kinoyama , Takehiro Miyazaki , Yohei Koganemaru , Takuya Washio , Wataru Hamaguchi
- Applicant Address: JP Chuo-Ku, Tokyo
- Assignee: Astellas Pharma Inc.
- Current Assignee: Astellas Pharma Inc.
- Current Assignee Address: JP Chuo-Ku, Tokyo
- Agency: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
- Priority: JP2009-183876 20090806
- International Application: PCT/JP2010/063240 WO 20100805
- International Announcement: WO2011/016504 WO 20110210
- Main IPC: A61K31/472
- IPC: A61K31/472 ; A61K31/47 ; A61K31/4709 ; A61P25/00 ; A61P25/18 ; A61P25/28 ; C07D215/48 ; C07D215/60 ; C07D217/14 ; C07D215/54 ; C07D217/02 ; C07D217/22 ; C07D217/16 ; C07D401/04

Abstract:
[Object] An excellent agent for preventing or treating dementia, schizophrenia, and the like, based on serotonin 5-HT5A receptor modulating action, is provided.[Means for Solution] It was confirmed that acylguanidine derivatives (the following formula I; any one of Z1, Z2, Z3, Z4 and Z5 is nitrogen atom, and the others are carbon atoms) which have the characteristic structure in which the guanidine is bonded to one ring of the quinoline or isoquinoline via a carbonyl group, and a cyclic group is bonded to the other ring, exhibit potent 5-HT5A receptor modulating actions and excellent pharmacological actions based on the 5-HT5A receptor modulating action, and thus can be excellent agents for preventing or treating dementia, schizophrenia, bipolar disorder, or attention deficit hyperactivity disorder. Thus, the present invention has been completed.
Public/Granted literature
- US20120142727A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE Public/Granted day:2012-06-07
Information query
IPC分类: